Concentra® to Announce Second Quarter 2024 Results on Thursday, August 1, 2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in biosimilar medicines, announced that the majority of holders of its subordinated convertible bonds will convert their holdings into ordinary shares. The conversion will occur on July 1, 2024, at a fixed price of $10.00 per share. Based on current exchange rates, Alvotech estimates issuing approximately 22.1 million new shares.
All holders of the ISK-denominated Convertible Bonds (Tranche A) have opted for conversion, with an aggregate value of about $183.1 million. For USD-denominated bonds, holders of approximately $38 million worth have chosen to convert, while holders of about $116.7 million have not exercised their conversion rights. The newly issued shares will be delivered within seven business days after the Conversion Date.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata in farmaci biosimilari, ha annunciato che la maggior parte dei detentori delle sue obbligazioni convertibili subordinate convertiranno le loro partecipazioni in azioni ordinarie. La conversione avverrà il 1° luglio 2024, a un prezzo fisso di 10,00 $ per azione. In base ai tassi di cambio attuali, Alvotech stima di emettere circa 22,1 milioni di nuove azioni.
Tutti i detentori delle Obbligazioni Convertibili denominate in ISK (Tranche A) hanno optato per la conversione, per un valore complessivo di circa 183,1 milioni di dollari. Per le obbligazioni denominate in USD, i detentori di obbligazioni per un valore di circa 38 milioni di dollari hanno scelto di convertire, mentre i detentori di circa 116,7 milioni di dollari non hanno esercitato i loro diritti di conversione. Le nuove azioni emesse saranno consegnate entro sette giorni lavorativi dalla Data di Conversione.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global especializada en medicamentos biosimilares, anunció que la mayoría de los tenedores de sus bonos convertibles subordinados convertirán sus participaciones en acciones ordinarias. La conversión tendrá lugar el 1 de julio de 2024, a un precio fijo de 10,00 $ por acción. Basándose en los tipos de cambio actuales, Alvotech estima emitir aproximadamente 22,1 millones de nuevas acciones.
Todos los tenedores de los Bonos Convertibles denominados en ISK (Tranche A) han optado por la conversión, con un valor total de aproximadamente 183,1 millones de dólares. Para los bonos denominados en USD, tenedores de bonos por un valor de aproximadamente 38 millones de dólares han elegido convertir, mientras que tenedores de aproximadamente 116,7 millones de dólares no han ejercido sus derechos de conversión. Las nuevas acciones emitidas se entregarán dentro de siete días hábiles después de la Fecha de Conversión.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품을 전문으로 하는 글로벌 생명공학 회사로, 대부분의 보조 전환사채 보유자가 보유 지분을 보통주로 전환할 것이라고 발표했습니다. 전환은 2024년 7월 1일에 고정 가격 10.00 $ per share로 이루어질 예정입니다. 현재 환율을 기준으로 Alvotech는 약 2210만 주의 새로운 주식을 발행할 것으로 예상하고 있습니다.
ISK로 표시된 전환사채(트랜치 A)의 모든 보유자가 전환을 선택했으며, 총 가치는 약 1억 8310만 달러입니다. USD로 표시된 채권의 경우, 약 3800만 달러 상당의 보유자가 전환을 선택했으며, 약 1억 1670만 달러 상당의 보유자는 전환 권리를 행사하지 않았습니다. 새로 발행된 주식은 전환 날짜로부터 7영업일 이내에 전달될 것입니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale spécialisée dans les médicaments biosimilaires, a annoncé que la majorité des détenteurs de ses obligations convertibles subordonnées vont convertir leurs participations en actions ordinaires. La conversion aura lieu le 1er juillet 2024, à un prix fixe de 10,00 $ par action. En fonction des taux de change actuels, Alvotech estime émettre environ 22,1 millions de nouvelles actions.
Tous les détenteurs des Obligations Convertibles libellées en ISK (Tranche A) ont opté pour la conversion, pour une valeur totale d'environ 183,1 millions de dollars. Pour les obligations libellées en USD, des détenteurs d'obligations d'environ 38 millions de dollars ont choisi de convertir, tandis que des détenteurs d'environ 116,7 millions de dollars n'ont pas exercé leurs droits de conversion. Les nouvelles actions émises seront livrées dans un délai de sept jours ouvrables après la date de conversion.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf biosimilare Arzneimittel spezialisiert hat, gab bekannt, dass die Mehrheit der Inhaber seiner nachrangigen Wandelschuldverschreibungen ihre Anteile in Stammaktien umwandeln wird. Die Umwandlung erfolgt am 1. Juli 2024 zu einem Festpreis von 10,00 $ pro Aktie. Basierend auf den aktuellen Wechselkursen schätzt Alvotech, etwa 22,1 Millionen neue Aktien auszugeben.
Alle Inhaber der ISK-denominierten Wandelschuldverschreibungen (Tranche A) haben sich für eine Umwandlung entschieden, mit einem Gesamtwert von etwa 183,1 Millionen $. Bei den in USD denominierten Anleihen haben Inhaber von etwa 38 Millionen $ beschlossen zu konvertieren, während Inhaber von etwa 116,7 Millionen $ ihre Umwandlungsrechte nicht ausgeübt haben. Die neu ausgegebenen Aktien werden innerhalb von sieben Geschäftstagen nach dem Umwandlungsdatum geliefert.
- Majority of convertible bondholders opting for conversion, potentially improving the company's debt structure
- Conversion of approximately $221.1 million worth of bonds into equity, potentially strengthening the balance sheet
- Fixed conversion price of $10.00 per share, which may be above the current market price
- Issuance of approximately 22.1 million new shares, leading to potential dilution for existing shareholders
- $116.7 million worth of USD-denominated bonds not converting, remaining as debt on the balance sheet
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, respectively, with maturity on December 20, 2025 (the “Convertible Bonds”) have elected to convert the principal and accrued interest into ordinary shares of Alvotech at the fixed conversion price of US
On the Conversion Date, Alvotech will issue new shares to the holders that have exercised their right to convert their Convertible Bonds. The total number of new shares that will be issued and delivered will depend on the prevailing exchange rate of the Icelandic krona against the U.S. dollar on June 27, 2024. Based on the current exchange rate, Alvotech estimates that approximately 22.1 million new shares will be issued. Pursuant to terms of the Convertible Bonds, the newly issued shares shall be delivered no later than seven business days after the Conversion Date.
The Convertible Bonds were issued in two tranches, denominated in Icelandic krona (ISK) and U.S. Dollars (USD), respectively. The ISK denominated Convertible Bonds were listed on the Nasdaq First North growth market in Iceland under the symbol ALVCVB251220.
All holders of the ISK denominated Convertible Bonds (“Tranche A Bonds”) exercised their right to conversion. The aggregate value of these bonds, with accrued interest, is ISK 25,483,970,823 (USD 183,127,126 at the current exchange rate), which will be converted into ordinary shares at the conversion price of USD 10.00 per share, at the exchange rate published by the Central Bank of Iceland on June 27, 2024. Based on current exchange rates, Alvotech estimates that approximately 18.3 million new shares will be issued to holders of Tranche A Bonds.
Holders of USD denominated Convertible Bonds for a value, with accrued interest, of USD 37,981,167 as of the Conversion Date, have exercised their right to conversion and will be issued 3,798,117 new shares on the Conversion Date.
Holders of USD denominated Convertible Bonds for an aggregate value, with accrued interest, of USD 116,677,563 as of the Conversion Date, have not exercised their right to conversion.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding the exchange rate of the Icelandic krona against the U.S. dollar on the Conversion Date and shares to be issued in connection with the conversion, the redemption of the convertible bonds, including whether the investors will elect to be settled in shares or in cash, Alvotech’s ability to satisfy conditions precedent to close and draw down the loans under the financing facility announced on June 7, 2024, to comply with the covenants of that facility, to exercise its rights under the facility, the expected use of proceeds from the facility, potential future financings or strategic transactions, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company’s business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, Senior Director
alvotech.ir@alvotech.com
FOR MORE INFORMATION
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
FAQ
When will Alvotech (ALVO) convert its subordinated convertible bonds into shares?
What is the conversion price for Alvotech's (ALVO) convertible bonds?
How many new shares will Alvotech (ALVO) issue due to the bond conversion?
What is the total value of Alvotech's (ALVO) convertible bonds being converted?
